Zydus Lifesciences Ltd.
NSE: ZYDUSLIFEZydus Lifesciences Ltd.: A 30-second snapshot
Zydus Lifesciences trades at Rs 1,114.2, up 16.14% over the past year and 18.73% over the past 3 months, sitting above both its 50-day (Rs 1,112.5) and 200-day (Rs 974) moving averages and just below its nearest resistance at Rs 1,114.5. The company carries a trailing PE of 22.22 against a forward PE of 23.63, ROE of 18.32%, and a quality score of 48/100, with a mean analyst rating of 2.57 across 30 analysts (1-5 scale, lower = more constructive). Recent news flow (8 items, 3 negative/1 positive) includes a USFDA generic-drug approval alongside a stamp-duty fine order and tariff-linked sector pressure.
P/E
22.2
Forward P/E
23.6
ROE
+18.3%
Debt / Equity
42.30
Profit Margin
+18.6%
Div. Yield
+0.1%
5Y ROE > 15%
3/5
5Y FCF > 0
3/5
Quality
61/100
News
8 headlines · 1 positive · 3 negative
Zydus Life gets USFDA nod for generic indocyanine green for injection - Business Standard
Business Standard
Zydus Lifesciences Q1 Results: Earnings call scheduled for Aug 11 - scanx.trade
scanx.trade
Zydus Lifesciences Ordered to Pay Deficient Stamp Duty, Fines for Asset Acquisition - marketscreener.com
marketscreener.com
Sun Pharma, Zydus Life, Dr Reddy's Labs, Lupin: Pharma shares crash on Trump's fresh tariffs - Business Today
Business Today
Zydus Lifesciences suspends some Ahmedabad operations due to heavy rain, resumes activity - CNBC TV18
CNBC TV18
Recent context
- ·Zydus Life received USFDA approval for generic indocyanine green injection on Aug 4, 2026 (Business Standard).
- ·The company was ordered to pay deficient stamp duty and fines related to an asset acquisition, per a July 29 report (marketscreener.com).
- ·Pharma stocks including Zydus Life, Sun Pharma, Dr Reddy's, and Lupin declined after fresh US tariff announcements in late July; Zydus also briefly suspended some Ahmedabad operations due to heavy rain before resuming activity.
Strengths
- +Price trades above both the 50-DMA (Rs 1,112.5) and 200-DMA (Rs 974), up 16.14% over 1 year and 18.73% over 3 months.
- +Trailing PE of 22.22 is the lowest among the 6 tracked pharma peers (APOLLOHOSP 66.22, CIPLA 35.09, DRREDDY 29.50, MAXHEALTH 72.44, SUNPHARMA 38.61).
- +ROE of 18.32% with 3 of the tracked years above the 15% threshold; ROE ranks 2nd of 6 within the sector peer set.
- +Received USFDA approval for generic indocyanine green injection on Aug 4, 2026, extending its US generics pipeline.
Weaknesses
- −5-year earnings CAGR (8.7%) trails the 5-year revenue CAGR (16.2%), and forward PE (23.63) exceeds trailing PE (22.22).
- −Debt-to-equity trend is reported as rising (current ratio near 0.42x equity), with free cash flow positive in only 3 of the years measured.
- −Quality score of 48/100 sits mid-pack, and recent news skews negative (3 of 8 headlines negative vs 1 positive), including a stamp-duty fine order tied to an asset acquisition.
- −Current price sits directly at its nearest resistance level (Rs 1,114.5), just 0.03% above Rs 1,114.2.
Open questions
- ?Does the gap between 5-year earnings growth (8.7%) and revenue growth (16.2%) reflect a temporary margin drag or a structural shift in cost or pricing?
- ?How exposed is Zydus's US generics revenue to the tariff actions referenced in recent coverage, and how does that compare with peers like Sun Pharma and Dr Reddy's?
- ?What is driving the rising debt-to-equity trend, and how does it align with the years free cash flow was negative?
- ?With price sitting right at the Rs 1,114.5 resistance level after an 18.73% 3-month advance, what factors would need to hold for the price to move through versus stall at this level?
Peer comparison: Pharma
Ranks 2 of 6 on quality| Symbol | Name | P/E | ROE | Quality |
|---|---|---|---|---|
| ZYDUSLIFE | Zydus Lifesciences Ltd.You're viewing | 22.2 | +18.3% | 48 |
| Industry avg | across 5 peers | 48.4 | +14.9% | 34 |
| SUNPHARMA | Sun Pharmaceutical Industries Ltd. | 38.6 | — | 57 |
| APOLLOHOSP | Apollo Hospitals Enterprise Ltd. | 66.2 | +21.5% | 44 |
| MAXHEALTH | Max Healthcare Institute Ltd. | 72.4 | +14.3% | 37 |
| CIPLA | Cipla Ltd. | 35.1 | — | 28 |
| DRREDDY | Dr. Reddy's Laboratories Ltd. | 29.5 | +8.8% | 4 |
Technical state
Current price
₹1,114.20
SMA 50
₹1,112.50
SMA 200
₹974.00
RSI (14)
48.5 (neutral)
From 52w high
-5.6%
1Y return
+16.1%
3M return
+18.7%
50-DMA
Above
200-DMA
Above
Algorithmic support levels
Algorithmic resistance levels
Risk flags
- medium5-year earnings CAGR of 8.7% trails the 5-year revenue CAGR of 16.2%, and forward PE (23.63) sits above trailing PE (22.22), indicating the market is pricing forward EPS growth that has not yet shown up in the trailing profitability record.
- mediumDebt-to-equity trend is reported as rising, with the current ratio near 0.42x equity, while free cash flow was positive in only 3 of the years measured, narrowing headroom for further leverage increases.
- lowCurrent price of Rs 1,114.2 sits just 0.03% below the nearest resistance level (Rs 1,114.5), placing it directly at an overhead supply zone identified from recent price action.
- mediumOf the 8 most recent headlines, 3 are classified negative and 1 positive (overall label: negative), including an order to pay deficient stamp duty and fines tied to an asset acquisition, and sector-wide declines after fresh US tariff announcements affecting pharma exporters.
Cross-section contradictions
- Price technicals show a constructive trend - up 16.14% over 1 year and 18.73% over 3 months, trading above both the 50-day (Rs 1,112.5) and 200-day (Rs 974) averages - while the 8 most recent news headlines skew negative (3 negative vs 1 positive) and the 5-year earnings CAGR (8.7%) trails the 5-year revenue CAGR (16.2%), suggesting the recent price advance has outpaced both near-term sentiment and the trailing profitability trend.
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 11 Aug 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 9 Aug 2026 · rotates through NIFTY 500 every ~5 days